U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    44.97
    -0.74 (-1.62%)
     
  • Gold

    1,813.70
    +2.50 (+0.14%)
     
  • Silver

    23.35
    -0.09 (-0.39%)
     
  • EUR/USD

    1.1916
    +0.0003 (+0.0238%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3355
    -0.0002 (-0.0147%)
     
  • USD/JPY

    104.1930
    -0.0570 (-0.0547%)
     
  • BTC-USD

    17,118.86
    -27.12 (-0.16%)
     
  • CMC Crypto 200

    335.96
    -34.56 (-9.33%)
     
  • FTSE 100

    6,362.93
    -28.16 (-0.44%)
     
  • Nikkei 225

    26,537.31
    0.00 (0.00%)
     

Top Research Reports for Novartis, Zoom Video & FIS

Sheraz Mian
·6 min read

Friday, October 16, 2020

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Fidelity National Information Services (FIS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Novartis shares have underperformed the Zacks Large-Cap Pharmaceuticals in the year to date period (-9.9% vs. -2.3%). The Zacks analyst believes that solid performance of key drugs like Cosentyx and Entresto, and contributions from Kisqali and gene therapy, Zolgensma, have also boosted the company’s performance in the recent past.

These drugs and new launches like Piqray, Mayzent and Beovu should further boost sales amid a slowdown due to the ongoing pandemic. The biosimilar portfolio also gains traction with new key approvals and is expected to drive growth. Novartis’ efforts to develop and diversify its pipeline are also impressive.

However, price erosion in the United States has adversely impacted the generics business. Moreover, pipeline setbacks and generic competition for key drugs are concerning. Shares have underperformed the industry in the past year. The company has tightened its outlook for 2020 due to the pandemic woes.

(You can read the full research report on Novartis here >>>)

Shares of Zoom Video have gained +734.8% over the past year against the Zacks Internet Software industry’s rise of 93.8%. The Zacks analyst believes that demand for the company’s cloud-native video-first platform is expected to remain solid owing to the work-from-home and online-learning wave.

Easy to deploy, use, manage and scalability makes Zoom Video’s software popular among its customers. Expanding clientele is expected to drive top-line growth momentum in the near term. Moreover, the company’s expanding international presence is a key catalyst.

Its efforts to eliminate the security and privacy loopholes, as well as new hardware and Zoom From Home solution’s launch, are expected to help in expanding clientele. The company’s strong free cash-flow generating ability is noteworthy. However, acute competition from the likes of Microsoft and Cisco in the video-communication space does not bode well.

(You can read the full research report on Zoom Video here >>>)

FIS shares have gained +14% over the past six months against the Zacks Financial Transaction Services industry’s rise of +19.1%. The Zacks analyst believes that the company remains well-poised for growth, backed by attractive core business with several ongoing initiatives and a broad customer base.

The acquisition of Worldpay will accelerate growth by expanding presence in fast-growing markets. Further, increasing investment in mobile banking and innovative products is likely to support Fidelity's growth.

Also, earnings estimates have been going down lately ahead of third-quarter results. The company remains exposed to rising costs on account of investment in technology, and consolidation in the banking sector. It faces credit risk in case of any economic downturn.

(You can read the full research report on FIS here >>>)

Other noteworthy reports we are featuring today include Amgen (AMGN), 3M Company (MMM) and TOTAL SE (TOT).

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>

Sheraz Mian

Director of Research                                                             

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

New Drugs Boost Novartis (NVS) Amid Generic Competition

Work-From-Home & Online Learning Wave Aids Zoom Video (ZM)

Acquisitions Support Fidelity (FIS) Amid Increasing Expenses

Featured Reports

Amgen (AMGN) Rides on Solid Pipeline and Regular Deals

Amgen expects several important data readouts from its pipeline in second-half 2020. It also pursues external opportunities as evident from the purchase of Otezla.

Product Demand & Cost Actions to Aid 3M (MMM) Amid Pandemic

Per a Zacks analyst, 3M (MMM) is poised to gain from a high demand for respirators and products for personal safety, home improvement, and others.

LNG Focus, Strong Production Portfolio Aid TOTAL (TOT)

Per the Zacks analyst TOTAL's focus to develop LNG assets globally and its strong production growth through a new startup is going to boost its performance.

FedEx (FDX) Rides High on Residential Volumes & Liquidity

The Zacks analyst is impressed by residential volume growth at the company's Ground unit. FedEx's strong liquidity position is an added positive.

Low Costs Aid CSX Amid Coronavirus-Led Weakness in Volumes

While a significant reduction in costs is aiding CSX, the Zacks analyst is concerned about the coronavirus-led volume softness.

Digital Transformation, AI Proliferation Aid Infosys (INFY)

Per the Zacks analyst, Infosys is benefiting from large deal wins and higher investments by clients in digital transformation, artificial intelligence and automation.

Vertex's (VRTX) Triple Combo CF Pill Key to Growth in 2020

Per the Zacks analyst, Vertex's sales in 2020 are being driven by the rapid uptake of Trikafta as well as higher international revenues.

New Upgrades

AutoZone's (AZO) Digital Ramp Up & Cost Cuts to Aid Profits

AutoZone's rising e-commerce efforts like the recently introduced curbside pick-up option, along with cost cut measures, are likely to boost the firm's bottom line in future, per the Zacks analyst.

Growth Investments & Rheinhutte Pumpen Buyout to Drive ITT

Per the Zacks analyst, ITT's innovation investments & initiatives to expand its manufacturing automation capabilities will boost its competency.

Rising Revenues, Lower Costs Aid Ensign Group (ENSG)

Per the Zacks analyst, its improving topline driven by Medicaid and Medicare businesses as well as strategic measures poises it well for growth.

New Downgrades

Electrification Plans to Drive Toyota (TM) Amid Weak Demand

While collaborations with Subaru and Mazda are likely to buoy Toyota's e-mobility prospects, coronavirus-led sluggish vehicle demand is hurting near-term profits, per the Zacks analyst.

Cruise Cancellations & Cash Burn Hurts Royal Caribbean (RCL)

Per the Zacks analyst, cruise cancellations and cash burn due to the coronavirus pandemic continues to hurt Royal Caribbean. Due to the pandemic, bookings for 2020 have declined significantly.

Murphy USA (MUSA) Hurt by Weak Gasoline Prices

The Zacks analyst believes that the weak gasoline prices might continue to hamper Murphy USA's bottom line. The company's high debt level is also a concern.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Zoom Video Communications, Inc. (ZM) : Free Stock Analysis Report
 
TOTAL S.A. (TOT) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
3M Company (MMM) : Free Stock Analysis Report
 
Fidelity National Information Services, Inc. (FIS) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research